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Abstract
Introduction: Adipose tissue can release hormones into the blood stream in
response to specific extracellular stimuli or changes in metabolic status. Resistin,
an adipose-secreted factor, is primarily involved in the modulation of insulin
sensitivity and adipocyte differentiation. Adiponectin, an adipocyte-specific
hormone with insulin sensitizing, anti-inflammatory and anti-atherogenic effects,
is reduced in obesity and type II diabetes. The aim of the study was to assess
the influence of maternal pre-existing diabetes on cord blood resistin and
adiponectin at birth in relation to neonatal anthropometric parameters and cord
blood insulin levels. 
Material and methods: A total of 60 term newborns were prospectively enrolled
and categorized into three groups: 20 were macrosomic infants of pre-gestational
diabetic mothers (group I), 20 were non-macrosomic infants of pre-gestational
diabetic mothers (group II) and 20 were healthy non-macrosomic infants born
to non-diabetic mothers serving as controls (group III). Infants’ anthropometric
indices were recorded. Cord blood samples for glucose, insulin, resistin and
adiponectin assay, together with maternal glycosylated haemoglobin were
obtained. 
Results: Serum insulin was increased while resistin and adiponectin were
significantly decreased in infants of diabetic mothers (IDMs) compared to the
control group. Serum glucose, insulin, resistin and adiponectin were comparable
in group I and II. Cord serum resistin correlated positively with cord blood glucose
in IDMs in both macrosomic and non-macrosomic groups. Cord serum insulin
correlated positively with triceps skinfold thickness in all studied neonates. Cord
serum resistin and adiponectin showed no correlation with neonatal
anthropometric indices. Multiple regression analysis demonstrated that insulin,
resistin and adiponectin together were highly correlated with birth weight, with
adiponectin as the one responsible for this positive correlation. 
Conclusions: Infants of diabetic mothers had elevated levels of cord serum insulin
and suppressed levels of cord serum resistin and adiponectin, suggesting that
the regulation of these metabolic pathways is probably operational before birth.
Levels were comparable in both macrosomic and non-macrosomic neonates.
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Introduction
Recent data have radically modified the concept of adipose tissue as
one solely devoted to energy storage and release. Adipose tissue is also
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an important endocrine organ. It can release
hormones into the blood stream in response to
specific extracellular stimuli or changes in metabolic
status [1]. These hormones are potentially involved
in the regulation of energy homeostasis, adipose
tissue development, and insulin sensitivity and may
be the targets for nutrient interactions relevant to
the likelihood of developing obesity with adverse
effects on glucose and lipid metabolism [2].
Resistin, a recently cloned adipose-secreted
factor, originally named by Steppan et al., for its
resistance to insulin (resist + in[sulin]) [3], is
primarily involved in the modulation of insulin
sensitivity and adipocyte differentiation [4]. Resistin
opposes the action of insulin in peripheral tissues
and has a physiological function in the maintenance
of blood glucose during fasting. It has been
proposed to link obesity with diabetes [5].
Circulating resistin levels were higher in obese than
lean individuals [6]. It has also been shown to
inhibit adipogenesis in vitro [7]. Felipe et al.
speculated that it may be a feedback regulator of
adipogenesis and a signal to restrict adipose tissue
formation [2].
Adiponectin is an adipose-specific plasma protein
that improves insulin sensitivity and possesses anti-
inflammatory and anti-atherogenic properties [8].
Adiponectin is paradoxically reduced in obesity [9],
despite being solely derived from adipose tissue in
humans [10]. Both type 2 diabetes and relative
insulin resistance in non-diabetic subjects are
associated with decreased adiponectin concen  -
trations [11].
Numerous studies have explored the role of
adipocytokines in intrauterine growth [12]. However,
at present, no information is available with respect
to resistin and adiponectin in intrauterine growth
and very little is known concerning the potential
function of resistin and adiponectin in the paediatric
population, especially in newborn infants. 
In this study we hypothesized that, being closely
related to insulin metabolism, serum resistin would
increase and serum adiponectin would decrease in
macrosomic infants of diabetic mothers and this
might be correlated with anthropometric measures.
Material and methods
This prospective case control study was
conducted on 60 neonates recruited from those
delivered in the Obstetrics and Gynaecology Hospital
and followed up in the Neonatal Intensive Care Unit,
Ain Shams University Hospital, in the period from
January 2007 to December 2007. The study was
approved by the ethical committee of the Paediatric
Department, Ain Shams University. Informed consent
was obtained from mothers before recruitment.
These neonates were divided into the following
groups. Group I included 20 full-term macrosomic
(birth weight > 4000 g) neonates to diabetic
mothers. Group II included 20 full-term non-
macrosomic (birth weight: 2500-4000 g) neonates to
diabetic mothers. Infants were born to mothers with
pre-gestational type I diabetes mellitus. Group III
included 20 healthy full-term non-macrosomic
(birth weight: 2500-4000 g) neonates of non-
diabetic mothers, matched for age and sex, serving
as controls. Neonates with preterm delivery,
congenital or perinatal infection, congenital
malformation, chromosomal abnormalities, infants
whose mothers received corticosteroids or other
hormonal therapy, infants with low Apgar scores,
or with any evidence and/or history of metabolic
disorders were not included in the study.
For all neonates complete medical and obstetric
history was taken laying stress on duration of
maternal diabetes, treatment, complications, control
especially during late gestation, drugs or hormonal
therapy, pre-pregnancy maternal weight, history of
previous macrosomic neonates, stillbirth or
abortion, perinatal history for premature rupture of
membranes, mode of delivery, and Apgar score 
at 1 min and 5 min. The gestational age of an infant
was assessed by the mother's last menstrual period
and/or early ultrasound dating, and cross-checked
with the new Ballard score examination after 
birth [13].
Thorough clinical examination was performed and
anthropometric measurements taken including: 
a) birth weight measured by a calibrated digital scale,
b) supine crown-heel length, c) ponderal index,
calculated as birth weight (kg)/length3 (cm3), 
d) skinfold thickness measured with a skinfold caliper:
1) triceps skinfold thickness was measured halfway
down the upper arm while the arm was lying in
a relaxed position, 2) biceps skinfold thickness was
measured by lifting a fold over the biceps in line with
the anterior border of the acromial process and the
antecubital fossa, 3) suprailiac skinfold thickness was
measured by taking a fold just above the iliac crest
along the anterior axillary line, 4) subscapular skinfold
thickness was measured laterally just below the angle
of the scapula.
Laboratory measurements were as follows: 
• Maternal blood samples were collected at the
time of delivery, put in EDTA tubes, centrifuged
and the separated plasma stored at –20°C for
assessment of glycosylated haemoglobin (HbA1c).
HbA1c was measured on a Beckman Synchron CX7
(Beckman Instruments, Galway, Ireland).
• Cord blood samples were withdrawn and divided
into 2 parts: 1 part was withdrawn into plain
tubes for glucose assay. The other part was
withdrawn into plain tubes for clotting,
centrifugation and serum separation then stored
at –70°C until used. 
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• Random blood sugar was measured from the
freshly separated serum using the glucose oxidase
method [14]. 
• Serum insulin was measured by ELISA (Biosource
INS-EASIA immunoassay kit) supplied by 
Euroupe S.A. (Rue de I’Industrie, 8-B-1400 Nivelles,
Belgium). This assay employs the quantitative
sandwich enzyme immunoassay technique.
A monoclonal antibody specific for insulin (MAb1)
is pre-coated onto a microplate. Calibrators and
samples are pipetted into the wells and any
insulin present is bound by the immobilized
antibody. Another enzyme-linked monoclonal
antibody directed against different epitopes of
insulin (MAb2) was added to the wells. Following
a wash to remove any unbound antibody-enzyme
reagent, a substrate solution was added to the
wells and colour developed in proportion to the
amount of insulin bound in the initial step. The
colour development was stopped and the
intensity of the colour was measured.
• Serum resistin levels were detected by ELISA
technique using the BioVendor Human Resistin
immunoassay kit. It is a quantitative sandwich
enzyme immunoassay technique in which goat
polyclonal anti-human resistin antibody is pre-
coated onto a microplate [3]. Calibrators and
samples are incubated in the wells and any resistin
present is bound by the immobilized antibody.
A biotin labelled polyclonal anti-human resistin
antibody was added to the wells. Following a wash
to remove any unbound antibody-enzyme reagent,
a substrate solution was added to the wells and
yellow colour developed in proportion to the
concentration of resistin. The colour development
was stopped and the intensity of the colour was
measured at 450 nm.
• Serum adiponectin levels were detected by ELISA
technique using the Biosource Human adipo  nectin
ELISA (Europe S.A. Rue de I'Industrie, 8-B-1400
Nivelles, Belgium). It is a quantitative direct
enzyme immunoassay technique in which
calibrators and samples are incubated with
horseradish peroxidase labelled anti-adiponectin
antibody coated onto a microplate [9]. After
a thorough wash, the conjugate bound to
adiponectin coated wells is allowed to react with
hydrogen peroxide/TBM substrate solution. The
reaction is stopped by addition of sulfuric acid
solution and absorbance of the resulting yellow
product is measured at 450 nm.
Statistical analysis
Data were analysed using Statistical Package for
the Social Sciences (SPSS) software computer
program version 13. Quantitative data were
described using mean ± standard deviation;
qualitative data were described in the form of
numbers and percentages. Student’s t-test of two
independent samples was used to compare
normally distributed quantitative variables while
Mann-Whitney test was used for non- parametric
data. χ2 test was used to compare qualitative
variables. The correlation between continuous
variables was analysed using Spearman correlation
coefficient (r). Multiple regression analysis was done
with birth weight as the dependent variable, and
insulin, resistin and adiponectin as the independent
variables. The probability of error at or less than
0.05 was considered significant, at 0.01 and 0.001
highly significant. 
Results
Demographic and laboratory characteristics of
patient and control groups are listed in Tables I, II.
Group I included 7 males and 13 females with mean
birth weight 4.44 ±0.44 kg, mean gestational age
Data IDMs (n = 40) Controls (n = 20) t/Z Value of p
mean ± SD mean ± SD
Maternal age [years] 30.30 ±3.62 26.40 ±2.89 t = 4.192 0.001
Maternal BMI [kg/m2] 32.59 ±4.26 28.86 ±3.39 t = 3.407 0.001
Gestational age [weeks] 37.48 ±0.55 38.65 ±1.23 Z = 4.112 < 0.001
Birth weight [kg] 3.95 ±0.64 3.49 ±0.31 Z = 3.118 0.002
Supine length [cm] 53.68 ±4.57 49.95 ±1.16 Z = 4.195 < 0.001
Ponderal index [kg/cm3] 2.28 ±0.059 2.26 ±0.022 Z = 0.123 0.724
Sex [male/female]                      26/14  10/10  
MOD [NVD/CS] 10/30 14/6
Maternal HbA1c [%] 7.64 ±0.82 – – –
Blood glucose [mg/dl] 52.33 ±9.69 56.40 ±9.33 Z = 1.444 0.149
BMI – body mass index, Z – Mann-Whitney U, t – Student’s t-test, MOD – mode of delivery, NVD – normal vaginal delivery, CS – caesarean section
Table I. Clinical and laboratory data of infants of diabetic mothers (group I and II) and control group
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37.55 ±0.60 weeks. All of them were delivered by
caesarean section. Group II included 7 males and
13 females with mean birth weight 3.46 ±0.37 kg,
mean gestational age 37.40 ±0.50 weeks. Ten
neonates (50%) were born by vaginal delivery and
10 neonates (50%) were delivered by caesarean
section. Group III included 10 males and 10 females,
with mean birth weight 3.49 ±0.31 kg, mean
gestational age 38.65 ±1.23 weeks. Fourteen
neonates (70%) were born by vaginal delivery and
6 neonates (30%) were delivered by caesarean
section. All skinfold thicknesses were highly
significantly increased in infants of diabetic mothers
(IDMs) compared to controls (p = 0.001) (Figure 1).
Serum insulin was highly significantly increased in
IDMs compared to the control group (p < 0.001). On
the other hand, serum resistin and adiponectin
were significantly decreased in IDMs compared to
the control group (p = 0.005, p = 0.017 respectively)
(Figure 2). Mothers of macrosomic IDMs had
increased history of previous macrosomic infants,
significantly poor control of diabetes, and highly
significantly increased HbA1c compared to those of
non-macrosomic IDMs (Table II). Mean gestational
age was comparable in macrosomic and non-
macrosomic IDMs (p = 0.399). Mean birth weight
and gestational age were highly significantly
increased in macrosomic compared to non-
macrosomic IDMs (p < 0.001, p < 0.001 respectively),
while mean ponderal index was comparable in the
two groups (p = 0.149). Serum glucose, insulin,
resistin and adi  po  nectin were comparable in group
I and II (Table II). Levels of cord insulin, resistin and
adiponectin were comparable in females and 
males of the control group (p = 0.09, p = 0.439 and 
p = 0.50 respectively). Female IDMs (n = 14) had
significantly higher cord insulin than males (n = 26)
(44.36 ±45.36 µU/l, 25.13 ±25.81 µU/l respectively,
p = 0.034) and highly significantly increased cord
resistin compared to males (17.68 ±7.28 ng/ml, 
10.0 ±5.46 ng/ml respectively, p = 0.002), while 
no sex difference was detected in adiponectin 
level among IDMs (female: 12.6 ±3 µg/ml, male: 10.5
±3.9 µg/ml, p = 0.715). Mode of delivery had no
Parameters Group I (n = 20) Group II (n = 20) Z/χ2 Value of
mean ± SD, n (%) mean ± SD, n (%) p
Duration of maternal DM [years] 5.35 ±2.65 5.55 ±1.98 Z = 0.271 0.788
Strict control of DM:     +ve 9 (45) 20 (100)
–ve 11 (55)
χ2 = 15.17 0.0001
History of previous       +ve 15 (79) 6 (37.5)
macrosomic baby:        –ve  4 (21) 10 (62.5)
χ2 = 8.23 0.016
Sex:                               Male 13 (65) 13 (65)
Female 7 (35) 7 (35)
χ2 = 0.000 1.00
Mode of delivery:         NVD 0 (0) 10 (50)
CS 20 (100) 10 (50)
χ2 = 13.33 < 0.001
Gestational age [weeks] 37.55 ±0.50 37.40 ±0.60 Z = 0.853 0.399
Birth weight [kg] 4.44 ±0.37 3.46 ±0.44 Z = 7.534 < 0.001
Supine length [cm] 56.20 ±2.03 51.15 ±5.03 Z = 4.161 < 0.001
Ponderal index [kg/cm3] 2.28 ±0.07 2.27 ±0.03 Z = 0.809 0.149
Triceps skinfold thickness [mm] 2.66 ±0.38 1.98 ±0.33 Z = 6.135 < 0.001
Biceps skinfold thickness [mm] 2.00 ±0.34 1.48 ±0.46 Z = 4.098 < 0.001
Suprailiac skinfold thickness [mm] 1.59 ±0.32 1.31 ±0.50 Z = 3.510 0.001
Subscapular skinfold thickness [mm] 1.65 ±0.41 1.20 ±0.59 Z = 2.809 0.008
Maternal HbA1c [%] 8.30 ±0.55 6.98 ±0.38 Z = 8.892 0.001
Blood glucose [mg/dl] 50.45 ±9.05 54.20 ±10.17 Z = 1.232 0.226
Serum insulin [µU/l] 38.55 ±46.13 25.17 ±15.23 Z = 1.231 0.226
Serum resistin [ng/ml] 12.60 ±5.73 12.78 ±8.42 Z = 0.077 0.939
Adiponectin [µg/ml] 9.75 ±3.22 10.29 ±2.99 Z = 0.549 0.586
DM – diabetes mellitus, BMI – body mass index, NVD – normal vaginal delivery, CS – caesarean section, Z – Mann-Whitney U, χ2 – chi square test,
+ve control of DM – optimal or suboptimal, –ve control of DM – poor 
Table II. Comparison between macrosomic and non-macrosomic infants of diabetic mothers as regards clinical and
laboratory parameters 
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effect on cord insulin, resistin and adiponectin in
controls (p = 0.406, p = 0.130, p = 0.21 respectively)
or in IDMs (p= 0.962, p= 0.348, p= 0.410 respectively).
Cord serum resistin correlated positively with
cord blood glucose in IDMs in both macrosomic 
(r = 0.522, p = 0.018) and non-macrosomic groups 
(r = 0.462, p = 0.041). Cord serum insulin correlated
positively with triceps skinfold thickness in group I
(r = 0.482, p = 0.031), group II (r = 0.484, p = 0.049)
and group III (r = 0.486, p = 0.03) and with maternal
HbA1c in group I (r = 0.481, p = 0.032). Adiponectin
showed a non-significant correlation with studied
variables. The three hormones showed a non-
significant correlation with one another. Cord serum
resistin and adiponectin showed no correlation with
neonatal anthropometric indices. Multiple regression
analysis demonstrated that the combined effect of
insulin, resistin and adiponectin was highly
correlated with birth weight, with adiponectin as
the one responsible for this positive correlation.  
Discussion
Exposure to maternal diabetes in utero is
associated with metabolic changes that may impact
body size, glucose and intermediary metabolism
with increased adiposity at birth, as well as
increases in fetal insulin [15].
This study demonstrated that IDMs encountered
a significantly lower mean gestational age, but
higher birth weight, length, triceps, biceps,
suprailiac and subscapular skinfold thickness in
comparison to the control group. Similar results
were reached by others [16, 17]. Maternal diabetes
during pregnancy results in characteristic
overgrowth of the fetus due to excess supply of
nutrients, especially glucose, and consequent
chronic overproduction of insulin [15].
In the present study, insulin was detectable in
umbilical serum of all neonates at concentrations
that ranged from 5 µU/l to 150 µU/l. A highly signi  -
ficant increase in umbilical serum insulin in IDMs
(both macrosomic and non-macrosomic groups)
com  pared to the control group was observed. Fetal
hyperinsulinaemia has been detected in offspring
of diabetic mothers both in utero by sampling of
amniotic fluid [18] and after birth by sampling of
cord blood [19]. Fetal insulin production appears to
be related to the extent of metabolic abnormality
in the fetus and is predictive of both later impaired
glucose tolerance and obesity [15].
Resistin was detectable in umbilical serum of all
neonates included in this study, at concentrations
that ranged from 4 ng/ml to 37 ng/ml. Similarly, Ng
et al. [7] detected resistin in preterm and full-term
healthy newborns and its concentrations were
comparable to those in adults. Moreover, resistin
has been discovered in human placenta and it has
been theorized to play a role in fetal energy
metabolism [20].
This study revealed a highly significant decrease
in umbilical serum resistin in IDMs (both macro  -
somic and non-macrosomic groups) compared to
the control group, suggesting that the regulation
of metabolic pathways by this hormone is probably
operational before birth. Insulin has been suggested
to be a major inhibitor of resistin production, which
was evident from the low resistin mRNA concen  -
trations in insulin resistance [21]. A potential reason
for suppressed resistin levels in IDMs is
hyperinsulinaemia encountered in them. As resistin
could play a pivotal role in inhibiting adipocyte
differentiation, the suppressive effect of insulin on
resistin might result in eliminating the constraint
on the development of new adipocytes. This
mechanism might partially explain the excess
accumulation of adipose tissue in utero in infants
of poorly controlled diabetic mothers [5].
This result confirmed those reached by others
who reported that infants of insulin-dependant
diabetic mothers were found to have significantly
lower serum resistin concentration compared with
the normal control group [22]. In addition, previous
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experimental studies reported that exogenous
insulin treatment caused a substantial reduction of
resistin mRNA in a time- and dose-dependent
fashion in 3T3-L1 adipocytes [23, 24].
In the present study, adiponectin was detectable
in umbilical serum of all neonates at concentrations
that ranged from 1.5 µU/l to 16 µU/l. Cord blood
adiponectin level was significantly decreased in
IDMs compared to the control group. This finding
confirmed previous studies [25, 26]. Furthermore,
others found a significant decrease in adiponectin
level in full-term LGA newborns in comparison to
the AGA group [27]. In contrast, others detected no
difference in adiponectin level between full-term
IDMs and the control group [28].
Concerning influence of sex on serum insulin,
resistin and adiponectin levels, the present study
showed that sex has no effect on their
concentrations in the control group. Similar results
were reached by others [25, 29].
On the other hand, female IDMs had a highly
significant increase in umbilical serum resistin and
insulin levels compared to male IDMs. The same
results were obtained by previous studies reporting
that female offspring of diabetic mothers had
higher insulin concentrations than male neonates
[16]. A similar finding as regards resistin was found
in adults. Increased resistin levels in females were
attributed to higher fat cell mass in the female than
the male body [30, 31]. In contrast, Ng et al. [22]
demonstrated no difference in circulating
concentrations of resistin and insulin between male
and female IDMs. 
This study revealed that the mode of delivery
had no influence on umbilical serum insulin, resistin
and adiponectin in both IDMs and control groups.
Similar results were demonstrated by others [25,
29]. On the other hand, Ng et al. [7] found that
serum resistin levels were significantly higher in
infants who were born vaginally than those
delivered by caesarean section. Elevated resistin
level may be related to stress or inflammation
induced by vaginal delivery, as resistin is influenced
by proinflammatory stimuli or cytokines.
To detect the association of umbilical serum
insulin, resistin and adiponectin with the
anthropometric indices, a comparison was done
between macrosomic and non-macrosomic IDMs.
This comparison showed that the concentrations
of umbilical serum insulin, resistin and adiponectin
were comparable in the two groups. Of the
anthropometric parameters studied, only triceps
skinfold thickness correlated positively with
umbilical serum insulin in all studied groups. In
partial accordance with these results, previous
studies showed a significant association between
serum insulin and birth weight and body length in
normal full-term neonates [7]. Other studies
reported a non-significant association between
serum insulin and anthropometric indices in a group
of IDMs [22] and in normal full-term neonates [29].
No correlation was observed between umbilical
serum resistin and neonatal anthropometric indices
in IDMs in both macrosomic and non-macrosomic
and control groups. These results are in agreement
with Ng et al. [22], who found no correlations
between serum resistin and neonatal anthropometric
parameters (birth weight, length, body mass index,
skinfold thickness) in IDMs, but they reported
a positive correlation between resistin level and
gestational age and anthropometric indices in
healthy full-term and preterm neonates of non-
diabetic mothers [7]. The pattern of increase of
plasma resistin level with advancing gestational age
may be related to upregulation of placental resistin
expression in late pregnancy. On the other hand,
others detected a negative correlation between
umbilical serum resistin and neonatal birth weight
in a group of healthy full-term neonates. As resistin
appears to have an inhibitory effect on adipose
conversion, restricting excessive proliferation and
accumulation of fat tissue, the low resistin level in
serum may reduce the inhibitory effect on
adipogenesis, and, accordingly, induce the excess
production of adipose tissue in the fetus [29]. Prior
studies in mice and humans have shown conflicting
results regarding the link between resistin and
obesity. Circulating resistin levels were found to be
elevated in genetic and diet induced models of
obesity [32]. Interestingly, regional variation in the
expression of resistin has also been observed in
humans. Higher resistin mRNA levels in visceral
compared with peripheral fat provides an
explanation for the increase in metabolic
abnormalities in abdominal obesity [21]. 
Although no correlation was observed between
umbilical serum adiponectin and neonatal
anthropometric indices in IDMs (macrosomic and
non-macrosomic) and control groups, multiple
regression analysis showed that the combined
effects of insulin, resistin and adiponectin were
highly correlated with birth weight, with adiponectin
as the one responsible for this positive correlation.
Previous studies confirmed this finding. One study
reported that the fetal weight to placental weight
ratio index was associated with adiponectin in
neonates of type 1 diabetic mothers and in the
control group [33]. In addition, cord blood high
molecular weight adiponectin level (the active form
of adiponectin) was a significant predictor of birth
weight and birth length in healthy full-term
newborns [34]. Others reported that cord blood
adiponectin concentration correlated positively with
birth weight, birth length and the sum of the 
4 skinfold thickness measurements in term neonates
[35]. Moreover, they added that birth length rather
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than body fatness was the only determinant of cord
blood adiponectin concentration.
On the other hand, others found no correlation
between adiponectin and birth weight when
limiting the study to full-term neonates [28]. They
hypothesized that adipose tissue possibly exerts
negative feedback on adiponectin levels only when
it reaches critical mass. Thus, when the total
adipose tissue is low, adiponectin positively
correlates with birth weight. However, when the
quantity of adipose tissue is abnormally high, as in
large for gestational age fetuses, the negative
feedback intensifies to a degree that depresses the
level of adiponectin. Both lack of correlation and
lower levels of adiponectin found by Mazakie et al.
[22] in large for gestational age fetuses support this
hypothesis.
In the present study, no significant correlation
was observed between umbilical serum insulin and
gestational age in all studied groups. Similar results
were obtained by others [7, 29]. In addition, no
significant correlation between either umbilical
serum resistin or adiponectin and gestational age
in macrosomic and non-macrosomic IDMs and
control groups was detected in this study. Similarly,
previous studies detected a non-significant
correlation between umbilical serum resistin and
gestational age in a group of healthy full-term
neonates [29]. On the other hand, Ng et al. [7], and
Pardo et al. [36], reported that serum resistin and
adiponectin levels are positively correlated with
gestational age and their concentrations are
significantly higher in term than in preterm infants,
suggesting that these hormones could be gestation
related and might play an important role in
regulating energy metabolism and adiposity in
utero. The increase in plasma concentrations with
advancing gestational age might merely reflect
a larger adipose tissue mass at the late stages of
pregnancy. Moreover, several studies have reported
that resistin is generated in the placenta and the
human resistin gene is expressed in human
placental tissue [20]. It is speculated that the
placental production of resistin constitutes the
principal cause of the increase in levels of serum
resistin with advancing gestational age [37].
Different results were obtained in the current study
as all of the neonates included were full-term
neonates.
In the current study, a significant positive
correlation was observed between umbilical serum
resistin and glucose level in both macrosomic and
non-macrosomic IDMs. This significant correlation
was not found in the control group. Functionally,
resistin impairs glucose tolerance, resists insulin
action, and increases hepatic glucose production
[38]. A similar positive correlation was detected in
adults [39]. In discordance with these results,
previous studies found no significant correlation
between serum resistin and serum glucose in
a group of IDMs [22] and in healthy full-term and
preterm neonates [7]. They reported that the lack of
a significant correlation between resistin and
glucose might suggest that resistin was not involved
directly in the regulation of metabolism in utero.
In the present study, neither umbilical serum
resistin nor adiponectin correlated with serum
insulin. Similar findings were reported in IDMs 
[22, 40] and in healthy full-term neonates [7, 29, 41].
Furthermore, Lee et al. [32] reported that neither
transcriptional regulation of the resistin gene nor
circulating resistin levels correlated with serum
insulin. However, others found a positive correlation
between serum resistin and insulin. A previous
study on rodents showed that resistin levels were
significantly elevated and concordant with
increasing levels of insulin [39]. A similar finding
was reported in humans, where resistin expression
was induced by insulin treatment [5, 42]. These
conflicting results could be attributed to differences
in study groups, different parameters within the
same group such as age and fitness, different
sampling procedures whether cultured adipocytes
or serum, and different measurement techniques
whether resistin mRNA or serum resistin
concentrations.
In the current study, no significant correlation
was found between umbilical serum resistin  and
maternal HbA1c in both macrosomic and non-
macrosomic IDMs. This result was similar to
previous studies reporting a non-significant
correlation between umbilical serum resistin and
maternal HbA1c in IDMs [22].     
In conclusion, infants of diabetic mothers had
elevated levels of cord serum insulin and
suppressed levels of cord serum resistin and
adiponectin, suggesting that the regulation of these
metabolic pathways is probably operational before
birth. Levels of the three hormones were comparable
in both macrosomic and non-macrosomic neonates.
Although no correlation was observed between
umbilical serum resistin and adiponectin individually
with neonatal anthropometric indices, their
combined effects together with insulin were highly
correlated with birth weight, with adiponectin as
the one responsible for this positive correlation.  
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